N
Google TrendPANTHERS VS BLUE JACKETS (200+) — Gameday 7: Florida Panthers at Columbus Blue Jackets
The 24/7 Global Portal

World News, Markets & Google Trends

Aggregated real-time headlines, trending Google search queries, and verified dispatches in one single page.

Google Trends:panthers vs blue jackets200+posiciones de atlético de madrid contra manchester united5000+devils vs red wings2000+lioness season 35000+tresoldi200+street fighter movie early reviews2000+luis díaz200+halle berry child custody hearing200+
Category:All HeadlinesWorld & GeopoliticsMarkets & EconomyTech & AIPoliticsSearch results for: "FDA Approves Tucatinib Mainten" (30 stories)

Top Headline Story

FDA Approves Treatment Combination for Maintenance of Patients with Advanced HER2-Positive Breast Cancer
Lead StoryBreast Cancer Research Foundationtech
4d ago

FDA Approves Treatment Combination for Maintenance of Patients with Advanced HER2-Positive Breast Cancer

<a href="https://news.google.com/rss/articles/CBMisAFBVV95cUxOaG5RMi1RVUFYaFctWVJvS3EwTW1wU0lheTExcm1PbFR5dEg0d0xIVjQybTJiWVE0NFdkdUpCaV96X0JWUnQxYWQtcERlSG14MU0xTnpQU2VJN3hQYXZVdmVUb1JnV3dkcHYwVjQwM0tiaUZMM29SS3JXVnotQWJUMHk3VjY0RlViZFJhREFWWHRzN3NQQ3pMTHNHX3cxY1diQzQzX0xpMTJCdm1mcTRCRQ?oc=5" target="_blank">FDA Approves Treatment Combination for Maintenance of Patients with Advanced HER2-Positive Breast Cancer</a>  <font color="#6f6f6f">Breast Cancer Research Foundation</font>

Read Full StoryRelated Trends

Google Trends & Trending Search Intelligence

Real-time search volume
200+22m ago

panthers vs blue jackets

Gameday 7: Florida Panthers at Columbus Blue Jackets

Filter stories
5000+32m ago

posiciones de atlético de madrid contra manchester united

La quinta para el 6

Filter stories
2000+32m ago

devils vs red wings

Roster Changes for Devils vs. Red Wings | PREVIEW | New Jersey Devils

Filter stories
5000+32m ago

lioness season 3

Thank Zoe Saldaña for ‘Lioness’ Season 3’s Perfect Cliff-Hanger

Filter stories

Search Results for "FDA Approves Tucatinib Mainten"

Updated every 3 minutes via FreeNewsApi, GNews, Currents API & Google News

29 stories displayed
FDA Approves Tucatinib Combination for HER2-Positive Breast Cancer Maintenance
Oncology News Centraltech

FDA Approves Tucatinib Combination for HER2-Positive Breast Cancer Maintenance

<a href="https://news.google.com/rss/articles/CBMiwwFBVV95cUxOMTNfN2o1a2ZPUlRIQlFnTjlsb1I2Vm92QndOTWc5M1RSZFdQWXhHRGdpRlpmSGttM3R1ZHZFSHg3Y285RGFUeThSUTFUcEUwYW9rUlVaWlNPVUFzV3U5MTZhUzhDY2xQREFsNWVWZWxqbVNSV056OGtwNHhfRjNyUGF2a3ZVd1NKT0QtNHF0eGlMMS1saXhEaG50bnZBaUFiQVk3c094QkdjdExiVGluZnVwWXBlVGYwZVNsaXZmdXdjYjQ?oc=5" target="_blank">FDA Approves Tucatinib Combination for HER2-Positive Breast Cancer Maintenance</a>  <font color="#6f6f6f">Oncology News Central</font>

Read Full StoryMore like this
FDA Approves Tucatinib Maintenance Treatment for Advanced HER2-Positive Breast Cancer
SurvivorNettech

FDA Approves Tucatinib Maintenance Treatment for Advanced HER2-Positive Breast Cancer

<a href="https://news.google.com/rss/articles/CBMi7gFBVV95cUxQNXEzZldoVXgzRjdtSmVfMTdNb0hRZnNhWHBHMGdGRV9ocHZsQ1lNQVo3LUJTN0ZrTUxyRkV4d2QtRHlDNVNuOW5pZ1VaZWtjTkE3amZVc2d0NXJhRnNibC0wNHBnM1NRX2F4d3ZlNGFjdVVtUXRGaDZiZXZWZ3JRVjZtcU5qOElsWkN5MTByNWI3blVLNWM1cDJURWVuNF94RGhmQVg1SnotNnlRNTdxakxVdjZDblRBa2NzMi1Vby1uX09wTWFiaDJUeHY4Z09rMWpvT3pxd3VqYy05VkNjLUFhUTMtNzg5ZEwxdEl3?oc=5" target="_blank">FDA Approves Tucatinib Maintenance Treatment for Advanced HER2-Positive Breast Cancer</a>  <font color="#6f6f6f">SurvivorNet</font>

Read Full StoryMore like this
FDA Approves Tucatinib Plus Trastuzumab/Pertuzumab as First-Line Maintenance in Advanced HER2+ Breast Cancer
OncLivetech

FDA Approves Tucatinib Plus Trastuzumab/Pertuzumab as First-Line Maintenance in Advanced HER2+ Breast Cancer

<a href="https://news.google.com/rss/articles/CBMi0gFBVV95cUxPb090RjNfWHRVMWNqLU1oQW4wNmFKc2ZGdDVlVUx4OFNUdFk3eVNBWEc3YU1wMHdtQ2RKX2JQZnA1NXEyY3ZZa1VJZl8yRUhrZ2FPOFdmWFFVQnNGZ0xDUEpXMFpwVjhQSUF5dVdtOXVqcjVfTHcwdkJhVkN3SlZNTk9DSlg1LTllZG1aeDFfWWttbm1HUzJQTXJiQmFpVWhPMlUwNVh4LS1xTFV4b2syTExNYl9OZ2NRcVlVb2tHbW9tX2FGcVdLM3dsa0VsVGs3Ync?oc=5" target="_blank">FDA Approves Tucatinib Plus Trastuzumab/Pertuzumab as First-Line Maintenance in Advanced HER2+ Breast Cancer</a>  <font color="#6f6f6f">OncLive</font>

Read Full StoryMore like this
FDA Approves Tucatinib Maintenance for HER2+ Metastatic Breast Cancer
AJMCtech

FDA Approves Tucatinib Maintenance for HER2+ Metastatic Breast Cancer

<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxQSFdYanNxUFFzNHE0bVlfOXpYVm9ieF96Yi1pQzE0cGVMYVdpLUQ0UTBDcDZyTDNGNnVxdm1FcnJYd0YtaW9PZS1QLXp0M1JNd3JveTJNY1RDQWUtUC15b2liQ2pVRjBaSldjbGxYTGJlcEZKbl9lSjNqN0tEQUwycHpwVm5oV1B2Q0xEcXNTX2VTZUtXQ21CcU1n?oc=5" target="_blank">FDA Approves Tucatinib Maintenance for HER2+ Metastatic Breast Cancer</a>  <font color="#6f6f6f">AJMC</font>

Read Full StoryMore like this
FDA Approves Tucatinib Maintenance Regimen in HER2+ Metastatic Breast Cancer
Targeted Oncologytech

FDA Approves Tucatinib Maintenance Regimen in HER2+ Metastatic Breast Cancer

<a href="https://news.google.com/rss/articles/CBMipgFBVV95cUxPbFRnb0FfTTVTVVJZdFJRWWZZWEtkQW9vN2J2NlJvMi1RLWM3RklINmdKVzh2REJVY01Zb2pLamMzWFl4Q2RiYjJJQmdGSXBDMXBDT21iU2ZqWGhhcUdfQmlkaTN4a1BtUDljbWdJeldXdFN6VkF4NXh2ZEtHQkdzSTJ2NkxkOUw1VUZZcU1KVXdBemlsbTBIMVQyT19wNzRyOEhfMEFB?oc=5" target="_blank">FDA Approves Tucatinib Maintenance Regimen in HER2+ Metastatic Breast Cancer</a>  <font color="#6f6f6f">Targeted Oncology</font>

Read Full StoryMore like this
FDA Approves Tucatinib Combo as Maintenance in HER2+ Breast Cancer
CancerNetworktech

FDA Approves Tucatinib Combo as Maintenance in HER2+ Breast Cancer

<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxOVVdCOURKay0wUFJSbWg1VlpDLVB5U1FXSzFIVmNHclNubHVSUlBiUVZWcjdoaUJZc1hpTmw4bG03bUpOSFhaTDZKQ1A1ejlDUTdFWWNOV3d3Y0hJRVJvN3VqcWUtNDlOOFBUbmEyeWI3a2NjX2tEV2laQ2Fhd2xLeWd0dGd2LWpVaDJpWTktYkpSVVpZVlI5cmliYWhoT09UMmc?oc=5" target="_blank">FDA Approves Tucatinib Combo as Maintenance in HER2+ Breast Cancer</a>  <font color="#6f6f6f">CancerNetwork</font>

Read Full StoryMore like this
FDA Approves Maintenance Tucatinib for Advanced HER2+ Breast Cancer
Oncology Nursing Newstech

FDA Approves Maintenance Tucatinib for Advanced HER2+ Breast Cancer

<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxNeEJXTFJyaWVhMkpkVXNIdTZpbXczdFpLcGVEWUhXWEw1QXBwN2pIZzdrUUY5eWg3WXZJcURiRzdxT1U4VHlsNXZGUklISjI4Nnc0TFZSajlGM2dkX3FLQTJEdWxNdmdWWVpsbUNkVzRyTUliN2ZGdm9ybV9hSUNrOTE1WHB1UFJ1T1pDOGdpQ0l3TFZta0RrWG96aEM3NXJIVDgxMQ?oc=5" target="_blank">FDA Approves Maintenance Tucatinib for Advanced HER2+ Breast Cancer</a>  <font color="#6f6f6f">Oncology Nursing News</font>

Read Full StoryMore like this
FDA Okays Tucatinib for HER2+ Breast Cancer Maintenance
Medscapetech

FDA Okays Tucatinib for HER2+ Breast Cancer Maintenance

<a href="https://news.google.com/rss/articles/CBMirgFBVV95cUxQd0F5OTNzY2szUnpIZGZvcFdKc29YdW5xWmo3akZ0ZGUzekxza0ZmRkNrdVZ0Y3Awb0JTYUhRR0hOdTYzZE4tMDRPNzg4ZnhzYUFPY1FpeGlPM1pmVG1JNXNaQnJxQWFIRTlTTHdiMWVwMkN0UFFLOUdwU3ZDWGVNY0ktZEw3cUhjenh1aG51Qjl3V0wweTJua1lmQUloM25ucVBHUGtqRVVhYzNYZFE?oc=5" target="_blank">FDA Okays Tucatinib for HER2+ Breast Cancer Maintenance</a>  <font color="#6f6f6f">Medscape</font>

Read Full StoryMore like this
FDA Approves Tucatinib as Front-Line Maintenance in HER2-Positive Metastatic Breast Cancer
Oncodailytech

FDA Approves Tucatinib as Front-Line Maintenance in HER2-Positive Metastatic Breast Cancer

<a href="https://news.google.com/rss/articles/CBMiYEFVX3lxTFAxUVZkS2tzRnNVRXMyU0dlS2k5bjlsYm4ybkJNVTJFck5DRFpkM2pfc20zdnA5NWRPcW4yX3JkenlWeDF5TVlMeVRMc0RURWwyZzZTLWozaTgtSy05WmxuMw?oc=5" target="_blank">FDA Approves Tucatinib as Front-Line Maintenance in HER2-Positive Metastatic Breast Cancer</a>  <font color="#6f6f6f">Oncodaily</font>

Read Full StoryMore like this
FDA Approves Tukysa Plus Trastuzumab and Pertuzumab as First-Line Maintenance Treatment for HER2-Positive Metastatic Breast Cancer
Pharmaceutical Executivetech

FDA Approves Tukysa Plus Trastuzumab and Pertuzumab as First-Line Maintenance Treatment for HER2-Positive Metastatic Breast Cancer

<a href="https://news.google.com/rss/articles/CBMisgFBVV95cUxQQXhheEFyaG9Zb2xQb2V1ZTZpZ1cyLUY0T0UxN014S2FMQUt3Y1doWGJaR0pTaWRmZGhpX0xzY3ZySjRhT04zeUtKV0JHcktSdFUzc2xHamRJbmRqMVRvTl90clVXRjlieF9aX05aT3R1NTBpWU55ZG5HTlJiRUZSTjlYcGgweG1ZRy01QUdaYVp2VkJ0TVhCOXNYa0k2WFpkX201elpTLWc1MENOcTltMHh3?oc=5" target="_blank">FDA Approves Tukysa Plus Trastuzumab and Pertuzumab as First-Line Maintenance Treatment for HER2-Positive Metastatic Breast Cancer</a>  <font color="#6f6f6f">Pharmaceutical Executive</font>

Read Full StoryMore like this
FDA Approves Tukysa Combination as Maintenance for HER2-Positive Breast Cancer
Cure Todaytech

FDA Approves Tukysa Combination as Maintenance for HER2-Positive Breast Cancer

<a href="https://news.google.com/rss/articles/CBMirgFBVV95cUxQTm5Cd3dkeHBLQkd5X01zRGhtNmVnN2RMWFdWQlJSamZlUmtvT3NRODA3VXlsSGxoQktlckx1Y19aYW5CcVNES1k0U0Q2d0JyWEpfYmNGaHpUdHR4dXBZRTRNMkE4NkZjNVNnLW1NSHNGdDdSckFqZ0JrVUw2MGxZS1lMSk9tTUI0TExEQXAzVlhLT09IWnE4VXpzbXpkbHpIcVVVdkExUzg2V3dkN3c?oc=5" target="_blank">FDA Approves Tukysa Combination as Maintenance for HER2-Positive Breast Cancer</a>  <font color="#6f6f6f">Cure Today</font>

Read Full StoryMore like this
FDA Approves Tukysa Maintenance Treatment for HER2-Positive Metastatic Breast Cancer
WebMDtech

FDA Approves Tukysa Maintenance Treatment for HER2-Positive Metastatic Breast Cancer

<a href="https://news.google.com/rss/articles/CBMipgFBVV95cUxPNXZOMEFnMzVvMkt2T3ZHS3BPUWtLNm1oOElhRlNRVEsxZF9UUzRuWnhtS0RsY1UyQ0xyWmJLeEFLMXZMTWVqbUE5U2tSOENNc1ZfVk9ZR3NUUnJRRS0tRzFHX2NBMlRWMXdfZ3p6M0xBMWVnVnQyVHBxbGI1VWs2R1dBMEpoMVBCX2pIRFZOdE9xWS16RWlsNF85dHVnTE5BOVpMek5B?oc=5" target="_blank">FDA Approves Tukysa Maintenance Treatment for HER2-Positive Metastatic Breast Cancer</a>  <font color="#6f6f6f">WebMD</font>

Read Full StoryMore like this
Tukysa Wins FDA Nod for First-Line HER2-Positive Breast Cancer Maintenance After Trial Showed 8.6-Month Longer Median Disease Control
Medical Dailytech

Tukysa Wins FDA Nod for First-Line HER2-Positive Breast Cancer Maintenance After Trial Showed 8.6-Month Longer Median Disease Control

<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxNb1NSV2FrN0VBZ3BDbUljMUFtbnZ2aURxOVg3aVl6NlNkc2c1c3hDcGVrU1pNTnFwNW54Q2dSc2g1M1Y4S3VBX0I5MmlFZTlhQTZqVTgyVWNoLTdaM3haS05GeVh4WTZLVmZKaGQ2TXhvQzZqbGg3NllBVnYzcmN1VHNkaEV5LXdESTIyWG1nNV9ialFfM0pLY2Z0djRWQQ?oc=5" target="_blank">Tukysa Wins FDA Nod for First-Line HER2-Positive Breast Cancer Maintenance After Trial Showed 8.6-Month Longer Median Disease Control</a>  <font color="#6f6f6f">Medical Daily</font>

Read Full StoryMore like this
FDA Approves Maintenance Tucatinib Regimen for HER2+ Breast Cancer
Oncology Nursing Newstech

FDA Approves Maintenance Tucatinib Regimen for HER2+ Breast Cancer

<a href="https://news.google.com/rss/articles/CBMipgFBVV95cUxQY0NQZ1lHa1BmcW8yLUdWWWYzZVI1eVR6a2V3VURVRWlDNFlZeGdpbU1HeFE3X3dfZVpxN0ZzdGhLanU0Zktic1FwMzE3aFZQSkxJVUMwNVVJXy11a2MwMEx4QUhKV1M1emFHRk0yVXNocFdEanp6b0xpLUdXUndGbWxOU2JuLS02VnU1VGp6eVQzRm9CUXhldW1LeVRIQkdQdWZZaXl3?oc=5" target="_blank">FDA Approves Maintenance Tucatinib Regimen for HER2+ Breast Cancer</a>  <font color="#6f6f6f">Oncology Nursing News</font>

Read Full StoryMore like this
Highlighting the FDA Approval of Maintenance Tucatinib-Based Therapy in Advanced HER2+ Breast Cancer
OncLivetech

Highlighting the FDA Approval of Maintenance Tucatinib-Based Therapy in Advanced HER2+ Breast Cancer

<a href="https://news.google.com/rss/articles/CBMiygFBVV95cUxPc1FuNHZWaVVjUnpsX0pNd2J1QlExYzR4MmtGWFZmVjBITHBmVXdZMk1CRDlWZkhMM2ZtVTdDRzY1RW01bWhxWjdIc1p2ZjQ3M2RYaVl2S2JmSVdsbU9BTG5BTFRuWFhiMUpicGszZXplSEZyTG1qSk9qTEZMYVZUUEJOWk1GcFRPbXFiRWtyOXM4S3IwcVgzYldUZEktSjJHNDJGd3Q4NThJQ255TV9GemJsX0NOUlJBdnlneVA2YmlXWTZibEx0bXVn?oc=5" target="_blank">Highlighting the FDA Approval of Maintenance Tucatinib-Based Therapy in Advanced HER2+ Breast Cancer</a>  <font color="#6f6f6f">OncLive</font>

Read Full StoryMore like this
Tatiana Prowell։ FDA Approves Tucatinib for Maintenance Therapy in HER2-Positive Advanced Breast Cancer
Oncodailytech

Tatiana Prowell։ FDA Approves Tucatinib for Maintenance Therapy in HER2-Positive Advanced Breast Cancer

<a href="https://news.google.com/rss/articles/CBMiYkFVX3lxTFBkOFdwM1hSR3U5WUVLdVNuSDc0cUdGN0lEeHpjaHQwbjJjREljcDdXLVNRRzBrc1NXOVEzbTVzLWtwd09odEFZNlM5aDFnQXJpZHpPaS1hVTVNNDZaRUFtNnVR?oc=5" target="_blank">Tatiana Prowell։ FDA Approves Tucatinib for Maintenance Therapy in HER2-Positive Advanced Breast Cancer</a>  <font color="#6f6f6f">Oncodaily</font>

Read Full StoryMore like this
Erika Hamilton: New FDA-Approved Maintenance Regimen Targets HER2-Positive Breast Cancer
Oncodailytech

Erika Hamilton: New FDA-Approved Maintenance Regimen Targets HER2-Positive Breast Cancer

<a href="https://news.google.com/rss/articles/CBMic0FVX3lxTFBtT2xxVFRDa3pEbUpiSnpYQnFYREk5Z1dMTXFCbUdrUnRRLU4wLXlIUDVKT3ZNbzM4bDBMd1ZWNFhzcmtmWXdSV2NCdDM0NnM3Q3ZqTEI5VmxHX0NsS2FrM0JGaUJOTlAxclV0VldqQkVZeDg?oc=5" target="_blank">Erika Hamilton: New FDA-Approved Maintenance Regimen Targets HER2-Positive Breast Cancer</a>  <font color="#6f6f6f">Oncodaily</font>

Read Full StoryMore like this
The OncFive: Top Oncology Articles for the Week of 10/4/2026
OncLivegeneral

The OncFive: Top Oncology Articles for the Week of 10/4/2026

<a href="https://news.google.com/rss/articles/CBMikgFBVV95cUxPV0Vzbjg3LUZpQThLSjNpNlpIQXY4WHQxbldibF9VZWZPWUM3OXpWRUkybzRBN1NMMHpXMDI2UDJPdURYZV9BSXV2a213NmtlS3gwekRycGpLQkpzZ1dJOWxxeUNLdjVqM3Z0OGFTWG9ZY1JFT2g1ZDlGSEVBdUp1RnZwR0lMVWc5YWlmT1lGMWZCZw?oc=5" target="_blank">The OncFive: Top Oncology Articles for the Week of 10/4/2026</a>  <font color="#6f6f6f">OncLive</font>

Read Full StoryMore like this
Dr Hamilton on Maintenance Tucatinib-Based Therapy for HER2+ Breast Cancer
OncLivetech

Dr Hamilton on Maintenance Tucatinib-Based Therapy for HER2+ Breast Cancer

<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxNQVJFUFNzcmVpNVJzSEw0cXRKeGtpeVQ2SFdnSFk0QVpDc211OUUycUE3Z3FTaHVqMWhYQldZVnRaZVVXbVI0VTJ3OXNNeC1TZFpEX29Fa2JNeW9xY3U2ZW12MkFzVzlFXzBjZElkSkZYMGtndEc1LS1OS1k1MzJubVMxcXc0bS1oTFFIbHoxaUtiazdoLUZ4d3hqcXF1ZllHV2FrQw?oc=5" target="_blank">Dr Hamilton on Maintenance Tucatinib-Based Therapy for HER2+ Breast Cancer</a>  <font color="#6f6f6f">OncLive</font>

Read Full StoryMore like this
Pfizer's Tukysa gets FDA clearance as front-line maintenance option in breast cancer
AllScitech

Pfizer's Tukysa gets FDA clearance as front-line maintenance option in breast cancer

<a href="https://news.google.com/rss/articles/CBMigwFBVV95cUxOTnlXTU5KOV85OHd6MkJhajhzT2dMVGJsOHprT1VSRlY1eUZpc2d1aWlndWxTcHVrdGdsNl9QamxEck4wWHJqTTFtMFBZREFUelpRcGUzTG9nMnVDRXJKaTJCYU5acXY3M3JpeFJibC1iazRFNTJmSWsxbG96elI2TzE0dw?oc=5" target="_blank">Pfizer's Tukysa gets FDA clearance as front-line maintenance option in breast cancer</a>  <font color="#6f6f6f">AllSci</font>

Read Full StoryMore like this
FDA Approves Palbociclib Plus Anti-HER2 and Endocrine Therapy as Maintenance in Breast Cancer
Targeted Oncologytech

FDA Approves Palbociclib Plus Anti-HER2 and Endocrine Therapy as Maintenance in Breast Cancer

<a href="https://news.google.com/rss/articles/CBMixAFBVV95cUxNNElFM0VTVHA2cnU2djdfRTF0UUN5NG8xRzN1bUJ6WF83RkwxZFVFMHg2UW1yTE5oS2dqQUppSVJVaVNCU1dJQTV0N0ZpZFU2ZEs2bGdOWmZYeU5IOGwxTTlrOGk0eFJSN0tYM1k4X1gwaURPT1hXSWMtcnJuVHlmbk4tVjZoT0VyNkJtQm54WXNiZE9ZREI1TUZoUVFBWVVGNjNfQUMtQ0dIWHNLVU1FbEY3eW8zU0xMcV9ucnd0aDBSMENS?oc=5" target="_blank">FDA Approves Palbociclib Plus Anti-HER2 and Endocrine Therapy as Maintenance in Breast Cancer</a>  <font color="#6f6f6f">Targeted Oncology</font>

Read Full StoryMore like this
FDA Approves Palbociclib for HR+/HER2+ Metastatic Breast Cancer Maintenance
Oncology Nursing Newstech

FDA Approves Palbociclib for HR+/HER2+ Metastatic Breast Cancer Maintenance

<a href="https://news.google.com/rss/articles/CBMirgFBVV95cUxPSWxBU25RWDVKNXg3ZVAwYXlZWXdfTWhKQzF3aGE4WDFBa0FaTHhDM0JIZmV2b056OEdrdV9CbW94aXIwdEZQa3lNLVctV1dmM2o2ODR4U05OXzhVa200UjFuaGp2Z0ZIbWNLRVJObmswRXVyUmdMTkR6VWhDZTZkMkt0aFduM1NBWk1yMS1kQWZqSmdEY1JfWlpkWFRXV2ViZ3F4QzNjNU50VGVIZkE?oc=5" target="_blank">FDA Approves Palbociclib for HR+/HER2+ Metastatic Breast Cancer Maintenance</a>  <font color="#6f6f6f">Oncology Nursing News</font>

Read Full StoryMore like this
After FDA Approves ADC Combo, Big Questions Remain in HER2-Positive Breast Cancer
Oncology News Centraltech

After FDA Approves ADC Combo, Big Questions Remain in HER2-Positive Breast Cancer

<a href="https://news.google.com/rss/articles/CBMiygFBVV95cUxNMGx2TTJ5REdKWDF2eTNRSHk1bmJYVl9JYkRZRW5TN2ZJRUxKcEVrSGo1Qm1KWl9RVkFVaWhhY3ptRUFPSWpmRV9mQ3IyQzRGTE5TbHhkZThIU3M5eS03SmlDQkxlMWlnQjZhcVBsRkpWRGxqRU9hMW5PUFF3Y01kUFFYMjFjM3I1aXowLXRUdVpYNXNWb1JpQTF1akpJYXhqOXVYZUxhZVY5aExKS3NUNF9JN2pJS2FDWkhvZ3VLMjJYWFVPTHN1VmV3?oc=5" target="_blank">After FDA Approves ADC Combo, Big Questions Remain in HER2-Positive Breast Cancer</a>  <font color="#6f6f6f">Oncology News Central</font>

Read Full StoryMore like this
Tucatinib Maintenance Extends PFS Across HER2+ Breast Cancer Subgroups
Targeted Oncologytech

Tucatinib Maintenance Extends PFS Across HER2+ Breast Cancer Subgroups

<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxOeDJCOTIxZVR1NXlhX3hRa212ODE2dndXZVdTT3ltdHU4OVRBejRsS3dxWC1CR190bFRZZDVGaXhaaEVRZmp0dUN2SExZMGUzWWhya3FlWE5ubm5LendOSUNvd2dZVE9UbmVRQjZVdlNHS3ozWGdDUWg5Rnd2dFo4aFp0THhxNkNoc3N0NWo5aXJtc2VRazZ2WVhoRDd0TWFvSVhQTg?oc=5" target="_blank">Tucatinib Maintenance Extends PFS Across HER2+ Breast Cancer Subgroups</a>  <font color="#6f6f6f">Targeted Oncology</font>

Read Full StoryMore like this
Dr Hamilton on Tucatinib Maintenance Efficacy in HER2+ Breast Cancer
Targeted Oncologytech

Dr Hamilton on Tucatinib Maintenance Efficacy in HER2+ Breast Cancer

<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxQYWVxWXliZ0VvU3FrWVlrN2lZN01MX25ZVGxhZVBMek9hbHF0MklUSnB6cEtYQkxsU095dFZOZjF4V044cTNoYXk3MlRIbUx4Z0ZmQzQ0RHNSb3ZSOXNaUmx3LVRxZUl6S3BrV2pfR0pCNTJfcEZhOFF5eFhadTVYSGNnc2VzSm95bXpBaFlick1xdThyYUFPNWFpLTF5ZU9Fd3c?oc=5" target="_blank">Dr Hamilton on Tucatinib Maintenance Efficacy in HER2+ Breast Cancer</a>  <font color="#6f6f6f">Targeted Oncology</font>

Read Full StoryMore like this
Tucatinib Maintenance Improves PFS Across Key Subgroups in HER2+ MBC
Targeted Oncologytech

Tucatinib Maintenance Improves PFS Across Key Subgroups in HER2+ MBC

<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxOS3dvZ21kTGhhWm5nYlhPLXo1NTlUeWE5VXBiYVJqbDhCbGswcHZGbFhCODJfVl96Y2Y2b0pBMnlXM2tCSmhWOHdCT3VoclRWY0xkRXVXVTdlNzBKTWFyaU9SQzFWMmFvMFpDbEJiclNRcDdjZnNPRklvdE5Ib1M2ZnFxMUNzWGlYU0pSSkZYWm16Y2I2TnRhNVh1b1pUSUJEbUE?oc=5" target="_blank">Tucatinib Maintenance Improves PFS Across Key Subgroups in HER2+ MBC</a>  <font color="#6f6f6f">Targeted Oncology</font>

Read Full StoryMore like this
Adding Tucatinib (Tukysa) to First-Line Maintenance Therapy Improves PFS in HER2+ Metastatic Breast Cancer
Oncology News Centraltech

Adding Tucatinib (Tukysa) to First-Line Maintenance Therapy Improves PFS in HER2+ Metastatic Breast Cancer

<a href="https://news.google.com/rss/articles/CBMi6wFBVV95cUxPSG9SYUpGbko3RmQ1X1FZWm9YbWtsX3l4bUF6ZDJVUFV1OEoyYk54N1hSZ0h1ekJoSnFCUjA5dG5OQjB2X2JtZVdiQ0lIUVA4b1FHd2hZNy1oU1dWME5JM0pYY2lleWZuRC1ielo5VTFmQmtyOHczdVNyMXZUNHFEVUtrVTNMa20zR3lhVjk1WW5DT1hWam45YU9LYWVSSGJITUVKVEFuSkc2Y1VBNzVGVXV5ZDFDZTRjeHRrS210d1hheTdrZ0ZIMzNfLVV4NWhTUVpDd2ZJMTdlcUNUa00xV0NLTTlWSkk3Ni1v?oc=5" target="_blank">Adding Tucatinib (Tukysa) to First-Line Maintenance Therapy Improves PFS in HER2+ Metastatic Breast Cancer</a>  <font color="#6f6f6f">Oncology News Central</font>

Read Full StoryMore like this
Tucatinib: Chemo-Sparing Maintenance for HER2+ Metastatic Breast Cancer
Targeted Oncologytech

Tucatinib: Chemo-Sparing Maintenance for HER2+ Metastatic Breast Cancer

<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxOaTdOU3VPblpYUlJfZ25FLVZhOU9lSzc2VWhLNHJSNnNCeWs1VkVobmRXU0tabndxWmR1OTZpcUI0LW96cTI1LWVldWYwRzI0S0pOelZWUi01VWhJRmRnT0hrMi1VWV91LVlkelFSczNvZFFQYVRKUjFwZ2hQdUlpZy1GY1o1VHFZTGZESVlNUzJSWmpNdF9hckJ4MUJJNE1jbkZHeA?oc=5" target="_blank">Tucatinib: Chemo-Sparing Maintenance for HER2+ Metastatic Breast Cancer</a>  <font color="#6f6f6f">Targeted Oncology</font>

Read Full StoryMore like this
Pfizer’s TUKYSA Regimen Receives FDA Approval as Front-Line Maintenance Treatment for HER2+ Metastatic Breast Cancer
Business Wiretech

Pfizer’s TUKYSA Regimen Receives FDA Approval as Front-Line Maintenance Treatment for HER2+ Metastatic Breast Cancer

<a href="https://news.google.com/rss/articles/CBMigAJBVV95cUxNRHlQUHpOdl9KcHlqN2Z3T2tjdkVONi02QjlfQlF4MlI0VzRpR3J5Mms3bE45NWFrdzdFYmJCRktUQzgxeWMwYkVaNW5ibmhQOUIxdENRRGJaTHZyaUdMamVKS0pQdnRkNkNFMU12NXJRLXlFWFlhN2VQQVhBZ25VQzBPbVd5b015enhaVmx2NldPOWlmdDJvbVBRTlFNRnNKcmVGck9wSGIwQUhNV2pSZUVXQWxTNkMwRXpwWWRYbFplRFZ6bjBiUDliNm1KRlJXalFOLVV2NXAzcFpoY3R6NTlOY2FfUlZBenN1NkJyenAxbkJiSGVYR2VfOEtxYlVx?oc=5" target="_blank">Pfizer’s TUKYSA Regimen Receives FDA Approval as Front-Line Maintenance Treatment for HER2+ Metastatic Breast Cancer</a>  <font color="#6f6f6f">Business Wire</font>

Read Full StoryMore like this
"FDA Approves Tucatinib Mainten" — Live Google News Trends & Headlines